Sirolimus

Major

Sirolimus Lisinopril Prinivil Explained Increased risk of angioedema Details Sirolimus Abrocitinib Cibinqo Explained Increased exposure of P-glycoprotein substrate Details Sirolimus Asciminib Scemblix Increased exposure to CYP3A4/P-gp substrates and increased risk of CYP3A4/P-gp substrates-related adverse effects Details Sirolimus Azathioprine Azasan An increased risk of hepatotoxicity Details Sirolimus Belumosudil Rezurock Explained Increased P-gp substrate exposure Details Sirolimus Benazepril Lotensin Increased risk of angioedema Details Sirolimus Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Sirolimus Captopril Capoten® Increased risk of angioedema Details Sirolimus Cyclosporine Injection Atopica Increased sirolimus exposure and an increased risk of sirolimus toxicity (anemia, leukopenia, thrombocytopenia, hypokalemia, diarr... Details Sirolimus Cyclosporine Ophthalmic Cequa Increased sirolimus exposure and an increased risk of sirolimus toxicity (anemia, leukopenia, thrombocytopenia, hypokalemia, diarr... Details Sirolimus Elacestrant Orserdu Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Sirolimus Enalapril Epaned Increased risk of angioedema Details Sirolimus Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Sirolimus Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Sirolimus Erdafitinib Balversa Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Sirolimus Fosinopril Monopril® Increased risk of angioedema Details Sirolimus Gilteritinib Xospata Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Sirolimus Ketoconazole Topical Extina® Foam Increased sirolimus exposure and an increased risk of sirolimus-related adverse reactions Details Sirolimus Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Sirolimus Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Sirolimus Lenacapavir Injection Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Sirolimus Lenacapavir Oral Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Sirolimus Letermovir Injection Prevymis Increased sirolimus exposure Details Sirolimus Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details Sirolimus Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Sirolimus Methotrexate Injection Abitrexate® Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Sirolimus Metoclopramide Injection Gimoti An increased risk of sirolimus toxicity (anemia, leukopenia, thrombocytopenia, hypokalemia, diarrhea) Details Sirolimus Metoclopramide Nasal Spray Gimoti An increased risk of sirolimus toxicity (anemia, leukopenia, thrombocytopenia, hypokalemia, diarrhea) Details Sirolimus Mitapivat Aqvesme Increased P-gp substrate exposure; reduced CYP3A substrate exposure Details Sirolimus Moexipril Univasc® Increased risk of angioedema Details Sirolimus Neratinib Nerlynx Increased exposure to P-gp substrate and risk of toxicity Details Sirolimus Nevirapine Viramune Reduced sirolimus exposure Details Sirolimus Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Sirolimus Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Sirolimus Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Sirolimus Perindopril Aceon Increased risk of angioedema Details